On January 29-30, 2025, the TBVI symposium took place in Les Diablerets, Switzerland, attracting over 120 researchers, developers, funders, and policymakers focused on tuberculosis (TB) vaccine research. Attendees included representatives from more than 60 research institutes, universities, and funding agencies across 20 countries. The event also featured two European research consortia, ITHEMYC and TBVACHORIZON, which coincided with the symposium to foster collaboration and knowledge exchange in the fight against tuberculosis. The symposium featured presentations on the challenges of designing TB vaccines, updates from vaccine developers about their ongoing candidates, and a session dedicated to community engagement. Additionally, there were lively debates aimed at challenging the audience’s perspectives on preclinical development and clinical trial strategies. These discussions aligned with the upcoming update of the TB Vaccine Development Pathway—a freely accessible web tool designed to guide professionals from discovery to implementation. If you’re curious to see more, you can watch the animation (click here) and explore the web tool www.tbvacpathway.org. Moreover, two talented scientists, Beatrice Francis and Andrew Simonson, received the TBVI Award. This award serves as a platform that allows emerging talent to showcase their work and engage with others in the field. TBVI is committed to creating opportunities for everyone involved in the fight against TB, whether they are emerging scientists or mothers participating in clinical trials with their infants. The Institut Pasteur of Madagascar presented a video (click here) showcasing the involvement of a mother and her baby in a TB vaccine clinical trial in Madagascar. TBVI thanks all participants for attending and contributing to the success of this symposium. We look forward to continuing our activities and initiating new initiatives together with the field. Presentations can be viewed here.